PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) today announced that it has entered into a research collaboration with Belgium’s Université Catholique de Louvain (UCL) and the UCL-affiliated Cliniques Universitaires Saint Luc (St. Luc Hospital) to further the development of the Company’s proprietary human liver engrafting cells (hLEC) as a potential cell-based liver therapy. Under the collaboration, the parties will use UCL-St. Luc Hospital’s recently established GMP cell processing facility to optimize procedures to derive hLEC and thereafter, the parties plan to initiate a clinical trial to evaluate the safety and preliminary efficacy of the hLEC as a treatment for children with liver-based metabolic disorders.
